ALKS
Alkermes plc
$26.49
Earnings Summary
Revenue | $218.84Mn |
Net Profits | $-43Mn |
Net Profit Margins | -19.65% |
Highlights
Alkermes plc’s revenue jumped 12.13% since last year same period to $218.84Mn in the Q2 2017. On a quarterly growth basis, Alkermes plc has generated 14.11% jump in its revenue since last 3-months.
Alkermes plc’s net profit jumped 8.89% since last year same period to $-43Mn in the Q2 2017. On a quarterly growth basis, Alkermes plc has generated 37.57% jump in its net profits since last 3-months.
Alkermes plc’s net profit margin jumped 18.74% since last year same period to -19.65% in the Q2 2017. On a quarterly growth basis, Alkermes plc has generated 45.29% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Alkermes plc post its latest quarter earnings
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Current Year | -0.12 |
Highlights
Alkermes plc’s earning per share (EPS) estimates for the current quarter stand at -0.12 - a -518.18% fall from last quarter’s estimates.
Alkermes plc’s earning per share (EPS) estimates for the current year stand at -0.12.
Key Ratios
Key ratios of the Alkermes plc post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Alkermes plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2023. This indicates that the Alkermes plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2016-07-28 | -0.1 | -0.01 | 90% |
2017-02-17 | 0.04 | 0.02 | -50% |
2016-11-02 | -0.05 | -0.09 | -80% |
2016-04-28 | -0.2 | -0.16 | 20% |
Company Information
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Organisation | Alkermes plc |
Headquarters | Connaught House, Dublin, Ireland, 4 |
Employees | 2280 |
Industry | Health Technology |
CEO | Richard F. Pops |
